BE2016C024I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2016C024I2 BE2016C024I2 BE2016C024C BE2016C024C BE2016C024I2 BE 2016C024 I2 BE2016C024 I2 BE 2016C024I2 BE 2016C024 C BE2016C024 C BE 2016C024C BE 2016C024 C BE2016C024 C BE 2016C024C BE 2016C024 I2 BE2016C024 I2 BE 2016C024I2
- Authority
- BE
- Belgium
- Prior art keywords
- factor viii
- inhibitory antibodies
- amino acid
- modified factor
- loci
- Prior art date
Links
- 102000001690 Factor VIII Human genes 0.000 abstract 4
- 108010054218 Factor VIII Proteins 0.000 abstract 4
- 229960000301 factor viii Drugs 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000002110 C2 domains Human genes 0.000 abstract 1
- 108050009459 C2 domains Proteins 0.000 abstract 1
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000057593 human F8 Human genes 0.000 abstract 1
- 229960000900 human factor viii Drugs 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/10—Factor VIII, AHF; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Glass Compositions (AREA)
- Fish Paste Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Specific amino acid loci of human factor VIII interact with inhibitory antibodies of hemophilia patients who have developed such antibodies after being treated with factor VIII. Modified factor VIII is disclosed in which the amino acid sequence is changed by a substitution at one or more of the specific loci. The modified factor VIII is not inhibited by inhibitory antibodies against the A2 or C2 domain epitopes. The modified factor VIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/523,656 US6458563B1 (en) | 1996-06-26 | 2000-03-10 | Modified factor VIII |
| PCT/US2001/005076 WO2001068109A1 (en) | 2000-03-10 | 2001-02-16 | Modified factor viii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE2016C024I2 true BE2016C024I2 (en) | 2020-01-30 |
Family
ID=24085870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE2016C024C BE2016C024I2 (en) | 2000-03-10 | 2016-05-02 |
Country Status (36)
| Country | Link |
|---|---|
| US (3) | US6458563B1 (en) |
| EP (1) | EP1280540B1 (en) |
| JP (1) | JP4044337B2 (en) |
| KR (1) | KR100485525B1 (en) |
| CN (1) | CN1191360C (en) |
| AT (1) | ATE391512T1 (en) |
| AU (2) | AU3841601A (en) |
| BE (1) | BE2016C024I2 (en) |
| BR (2) | BRPI0109131B8 (en) |
| CA (1) | CA2400295C (en) |
| CY (2) | CY1108179T1 (en) |
| CZ (1) | CZ298250B6 (en) |
| DE (1) | DE60133541T2 (en) |
| DK (1) | DK1280540T3 (en) |
| EE (1) | EE05075B1 (en) |
| ES (1) | ES2304379T3 (en) |
| FR (1) | FR16C0016I2 (en) |
| HK (1) | HK1051004A1 (en) |
| HU (2) | HU227804B1 (en) |
| IL (2) | IL151371A0 (en) |
| LT (1) | LTC1280540I2 (en) |
| LU (1) | LU93049I2 (en) |
| ME (1) | ME00601B (en) |
| MX (1) | MXPA02008798A (en) |
| NL (1) | NL300808I2 (en) |
| NO (2) | NO331935B1 (en) |
| NZ (1) | NZ520799A (en) |
| PL (1) | PL202936B1 (en) |
| PT (1) | PT1280540E (en) |
| RS (1) | RS50364B (en) |
| RU (1) | RU2285724C2 (en) |
| SI (1) | SI1280540T1 (en) |
| SK (1) | SK286205B6 (en) |
| UA (1) | UA75064C2 (en) |
| WO (1) | WO2001068109A1 (en) |
| ZA (1) | ZA200206810B (en) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| AU2002248329B2 (en) * | 2001-01-12 | 2007-06-28 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| CA2461443C (en) | 2001-10-05 | 2011-07-12 | Emory University | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| WO2003047507A2 (en) * | 2001-11-30 | 2003-06-12 | Emory University | Factor viii c2 domain variants |
| GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7709224B2 (en) * | 2003-06-03 | 2010-05-04 | Biosante Pharmaceuticals, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| ES2289528T3 (en) * | 2003-06-26 | 2008-02-01 | Merck Patent Gmbh | THROMBOPOYETIN PROTEINS WITH IMPROVED PROPERTIES. |
| US20050059023A1 (en) * | 2003-09-16 | 2005-03-17 | Cantor Thomas L. | Methods and kits for monitoring resistance to therapeutic agents |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| US7855274B2 (en) * | 2003-12-03 | 2010-12-21 | University Of Rochester | Recombinant factor VIII having increased specific activity |
| SI1750733T1 (en) * | 2004-05-03 | 2014-03-31 | Emory University | METHOD OF ADMINISTERING PORCINE B-DOMAINLESS fVIII |
| WO2005123928A1 (en) * | 2004-06-08 | 2005-12-29 | Battelle Memorial Institute | Production of human coagulation factor viii from plant cells and whole plants |
| DK2371856T3 (en) * | 2004-11-12 | 2022-08-08 | Bayer Healthcare Llc | Site-directed modifikation af FVIII |
| WO2006063031A2 (en) * | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| JP2009518345A (en) | 2005-12-07 | 2009-05-07 | テフニーシェ ウニヴェルジテート ミュンヘン | Affinity ligands of small peptides and peptidomimetics for factor VIII and factor VIII-like proteins |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| ES2349024T3 (en) * | 2006-04-11 | 2010-12-21 | Csl Behring Gmbh | METHOD TO INCREASE THE IN VIVO RECOVERY OF THERAPEUTIC POLYPEPTIDES. |
| US7939632B2 (en) * | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
| JP5448839B2 (en) * | 2006-12-22 | 2014-03-19 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | Modified clotting factor with long half-life in vivo |
| EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| FR2913020B1 (en) * | 2007-02-23 | 2012-11-23 | Biomethodes | NEW VIII FACTORS FOR THE TREATMENT OF TYPE A HEMOPHILS |
| EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| AU2008319183B2 (en) | 2007-11-01 | 2014-09-04 | University Of Rochester | Recombinant factor VIII having increased stability |
| EP2149603A1 (en) | 2008-07-28 | 2010-02-03 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
| EP3178835B1 (en) | 2009-02-03 | 2019-04-10 | Amunix Pharmaceuticals, Inc. | Extended recombinant polypeptides and compositions comprising same |
| CA2764872C (en) | 2009-06-09 | 2018-07-24 | Prolong Pharmaceuticals, LLC | Hemoglobin compositions |
| US20120263701A1 (en) | 2009-08-24 | 2012-10-18 | Volker Schellenberger | Coagulation factor vii compositions and methods of making and using same |
| US20130123181A1 (en) * | 2009-11-13 | 2013-05-16 | Kathleen Pratt | Factor VIII T Cell Epitope Variants Having Reduced Immunogenicity |
| WO2011069164A2 (en) | 2009-12-06 | 2011-06-09 | Biogen Idec Ma Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| WO2011088391A2 (en) * | 2010-01-14 | 2011-07-21 | Haplomics, Inc. | Predicting and reducing alloimmunogenicity of protein therapeutics |
| US20130216513A1 (en) | 2010-07-09 | 2013-08-22 | Biogen Idec Hemophilia Inc. | Chimeric Clotting Factors |
| WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
| MX347503B (en) * | 2010-11-05 | 2017-04-26 | Baxalta Inc | A new variant of antihemophilic factor viii having increased specific activity. |
| AU2012204328A1 (en) * | 2011-01-05 | 2013-07-11 | Expression Therapeutics, Llc | Method and system for suspension cell culture |
| ES2724778T3 (en) | 2011-06-10 | 2019-09-16 | Bioverativ Therapeutics Inc | Procoagulant compounds and procedures for their use |
| KR101829603B1 (en) | 2011-07-08 | 2018-02-19 | 바이오버라티브 테라퓨틱스 인크. | Factor viii chimeric and hybrid polypeptides, and methods of use thereof |
| WO2013016454A1 (en) | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
| CN102277379B (en) * | 2011-08-18 | 2013-07-24 | 中国科学院遗传与发育生物学研究所 | Expression vector for expressing coagulation factor VIII and application thereof |
| SI2804623T1 (en) | 2012-01-12 | 2020-02-28 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| PT3453402T (en) | 2012-01-12 | 2021-10-26 | Puget Sound Blood Center | Reducing immunogenicity against factor viii in individuals undergoing factor viii therapy |
| CN104487452A (en) | 2012-02-15 | 2015-04-01 | 阿穆尼克斯运营公司 | Factor viii compositions and methods of making and using same |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
| US10202595B2 (en) | 2012-06-08 | 2019-02-12 | Bioverativ Therapeutics Inc. | Chimeric clotting factors |
| US10287564B2 (en) | 2012-06-08 | 2019-05-14 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| EP2870250B2 (en) | 2012-07-06 | 2022-06-29 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| US10138291B2 (en) | 2012-07-11 | 2018-11-27 | Bioverativ Therapeutics Inc. | Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof |
| US10001495B2 (en) | 2012-07-25 | 2018-06-19 | Bioverativ Therapeutics Inc. | Blood factor monitoring assay and uses thereof |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| US20150266944A1 (en) | 2012-10-30 | 2015-09-24 | Biogen Idec Ma Inc. | Methods of Using FVIII Polypeptide |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| EP4223772A3 (en) | 2013-02-15 | 2023-10-18 | Bioverativ Therapeutics Inc. | Optimized factor viii gene |
| JP6387392B2 (en) | 2013-03-15 | 2018-09-05 | バイオベラティブ セラピューティクス インコーポレイテッド | Factor IX polypeptide preparation |
| EP4122487A1 (en) | 2013-03-15 | 2023-01-25 | Bioverativ Therapeutics Inc. | Factor viii polypeptide formulations |
| SG10201710616XA (en) | 2013-06-28 | 2018-02-27 | Biogen Ma Inc | Thrombin cleavable linker with xten and its uses thereof |
| EP3043813B1 (en) | 2013-08-08 | 2021-01-13 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
| TW202003554A (en) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | Factor VIII-XTEN fusions and uses thereof |
| CA2928314A1 (en) | 2013-10-22 | 2015-04-30 | Dbv Technologies | Method of treating haemophilia by inducing tolerance to blood factors |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| WO2015085276A1 (en) | 2013-12-06 | 2015-06-11 | Biogen Idec Ma Inc. | Population pharmacokinetics tools and uses thereof |
| EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| RS63583B1 (en) | 2014-01-10 | 2022-10-31 | Bioverativ Therapeutics Inc | Factor viii chimeric proteins and uses thereof |
| KR102382402B1 (en) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | Use of cation-exchange chromatography in the flow-through mode to enrich post-translational modifications |
| CA2940127A1 (en) * | 2014-02-19 | 2015-08-27 | Bloodworks | Factor viii b cell epitope variants having reduced immunogenicity |
| WO2015132724A1 (en) | 2014-03-05 | 2015-09-11 | Pfizer Inc. | Improved muteins of clotting factor viii |
| MA40864A (en) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | HYPOTAURINE, GABA, BETA-ALANINE AND CHOLINE FOR THE REGULATION OF THE ACCUMULATION OF RESIDUAL BY-PRODUCTS IN MAMMAL CELL CULTURE PROCESSES |
| JP6909203B2 (en) | 2015-08-03 | 2021-07-28 | バイオベラティブ セラピューティクス インコーポレイテッド | Factor IX fusion proteins and their production and usage |
| PE20231949A1 (en) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTS OF FACTOR VIII REDUCED WITH CpG, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASY DISORDERS |
| TWI850587B (en) | 2015-11-13 | 2024-08-01 | 日商武田藥品工業股份有限公司 | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| MY190067A (en) | 2015-11-13 | 2022-03-24 | Baxalta Inc | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| BR112018015659A2 (en) | 2016-02-01 | 2018-12-26 | Bioverativ Therapeutics Inc | optimized factor viii genes |
| CN109790529A (en) | 2016-06-24 | 2019-05-21 | 财团法人牧岩生命科学研究所 | Chimeric protein and application thereof comprising FVIII the and vWF factor |
| MA46967A (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc | METHODS OF TREATMENT OF HEMOPHILIC ARTHROPATHY USING CHEMERICAL COAGULATION FACTORS |
| KR20190091292A (en) | 2016-12-02 | 2019-08-05 | 바이오버라티브 테라퓨틱스 인크. | How to Induce Immune Resistance to Coagulation Factors |
| US11633504B2 (en) | 2017-05-09 | 2023-04-25 | Emory University | Nucleic acids encoding clotting factor variants and their use |
| AU2018313921B2 (en) | 2017-08-09 | 2024-12-19 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof |
| KR20200118089A (en) | 2018-02-01 | 2020-10-14 | 바이오버라티브 테라퓨틱스 인크. | Use of lentiviral vectors expressing factor VIII |
| EP3773517A1 (en) | 2018-04-04 | 2021-02-17 | Sigilon Therapeutics, Inc. | Implantable particles and related methods |
| TW202015723A (en) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | Methods of treating hemophilia a |
| AU2019306194A1 (en) | 2018-07-16 | 2021-02-04 | Baxalta GmbH | Gene therapy of hemophilia A using viral vectors encoding recombinant FVIII variants with increased expression |
| BR112021002017A2 (en) | 2018-08-09 | 2021-05-11 | Bioverativ Therapeutics Inc. | nucleic acid molecules and their uses for non-viral gene therapy |
| UY38389A (en) | 2018-09-27 | 2020-04-30 | Sigilon Therapeutics Inc | IMPLANTABLE DEVICES FOR CELLULAR THERAPY AND RELATED METHODS |
| TWI851647B (en) | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| BR112021025426A2 (en) | 2019-06-19 | 2022-06-21 | Bioverativ Therapeutics Inc | Recombinant factor viii-fc for the treatment of hemophilia and low bone mineral density |
| WO2020257586A2 (en) | 2019-06-20 | 2020-12-24 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
| WO2021119357A2 (en) | 2019-12-12 | 2021-06-17 | Baxalta Incorporated | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| WO2021262963A1 (en) | 2020-06-24 | 2021-12-30 | Bioverativ Therapeutics Inc. | Methods for the removal of free factor viii from preparations of lentiviral vectors modified to express said protein |
| TW202246505A (en) * | 2021-03-05 | 2022-12-01 | 俄羅斯聯邦商亞那拜恩有限公司 | Codon-optimized nucleic acid that encodes coagulation factor ix protein, and use thereof |
| WO2022212162A1 (en) * | 2021-03-31 | 2022-10-06 | Haemonetics Corporation | Hemostasis measurement device quality control formulations |
| WO2022264040A1 (en) | 2021-06-14 | 2022-12-22 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression |
| AR126846A1 (en) | 2021-08-23 | 2023-11-22 | Bioverativ Therapeutics Inc | OPTIMIZED FACTOR VIII GENES |
| JP2024537797A (en) | 2021-09-30 | 2024-10-16 | バイオベラティブ セラピューティクス インコーポレイテッド | Nucleic acids encoding factor VIII polypeptides with reduced immunogenicity - Patent Application 20070123333 |
| WO2024081309A1 (en) | 2022-10-11 | 2024-04-18 | Sigilon Therapeutics, Inc. | Engineered cells and implantable elements for treatment of disease |
| WO2025008774A1 (en) | 2023-07-05 | 2025-01-09 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| EP0182448A3 (en) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Production of factor viii and related products |
| ES8801674A1 (en) * | 1985-04-12 | 1988-02-16 | Genetics Inst | Novel procoagulant proteins. |
| JPH0387173A (en) | 1987-09-10 | 1991-04-11 | Teijin Ltd | Preparation of human active natural type factor viii c and transformant using the same |
| DK162233C (en) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | PROCEDURE FOR INSULATING FACTOR VIII FROM BLOOD PLASMA AND PHARMACEUTICAL PREPARATION CONTAINING THE ASSOCIATED PHATAR VIII |
| US6180371B1 (en) * | 1996-06-26 | 2001-01-30 | Emory University | Modified factor VIII |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5663060A (en) | 1992-04-07 | 1997-09-02 | Emory University | Hybrid human/animal factor VIII |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| WO1997003193A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| AU6291896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs comprising factor v domains or subdomains |
| HUP0301179A3 (en) * | 2000-09-19 | 2006-11-28 | Univ Emory | Modified factor viii |
| WO2003047507A2 (en) * | 2001-11-30 | 2003-06-12 | Emory University | Factor viii c2 domain variants |
| US7105745B2 (en) * | 2002-12-31 | 2006-09-12 | Thomas & Betts International, Inc. | Water resistant electrical floor box cover assembly |
-
2000
- 2000-03-10 US US09/523,656 patent/US6458563B1/en not_active Expired - Lifetime
-
2001
- 2001-02-16 AT AT01910853T patent/ATE391512T1/en active
- 2001-02-16 ES ES01910853T patent/ES2304379T3/en not_active Expired - Lifetime
- 2001-02-16 RU RU2002124123/13A patent/RU2285724C2/en active
- 2001-02-16 CA CA2400295A patent/CA2400295C/en not_active Expired - Lifetime
- 2001-02-16 MX MXPA02008798A patent/MXPA02008798A/en active IP Right Grant
- 2001-02-16 RS YUP-680/02A patent/RS50364B/en unknown
- 2001-02-16 CN CNB018063179A patent/CN1191360C/en not_active Expired - Lifetime
- 2001-02-16 IL IL15137101A patent/IL151371A0/en unknown
- 2001-02-16 JP JP2001566673A patent/JP4044337B2/en not_active Expired - Lifetime
- 2001-02-16 DK DK01910853T patent/DK1280540T3/en active
- 2001-02-16 AU AU3841601A patent/AU3841601A/en active Pending
- 2001-02-16 BR BRPI0109131A patent/BRPI0109131B8/en not_active IP Right Cessation
- 2001-02-16 NZ NZ520799A patent/NZ520799A/en not_active IP Right Cessation
- 2001-02-16 SK SK1439-2002A patent/SK286205B6/en not_active IP Right Cessation
- 2001-02-16 BR BR122013026957A patent/BR122013026957A8/en not_active Application Discontinuation
- 2001-02-16 KR KR10-2002-7011843A patent/KR100485525B1/en not_active Expired - Lifetime
- 2001-02-16 EP EP01910853A patent/EP1280540B1/en not_active Expired - Lifetime
- 2001-02-16 ME MEP-2009-82A patent/ME00601B/en unknown
- 2001-02-16 UA UA2002097145A patent/UA75064C2/en unknown
- 2001-02-16 PL PL359672A patent/PL202936B1/en unknown
- 2001-02-16 AU AU2001238416A patent/AU2001238416B2/en active Active
- 2001-02-16 SI SI200130823T patent/SI1280540T1/en unknown
- 2001-02-16 WO PCT/US2001/005076 patent/WO2001068109A1/en active IP Right Grant
- 2001-02-16 CZ CZ20023346A patent/CZ298250B6/en unknown
- 2001-02-16 DE DE60133541T patent/DE60133541T2/en not_active Expired - Lifetime
- 2001-02-16 EE EEP200200510A patent/EE05075B1/en active Protection Beyond IP Right Term
- 2001-02-16 PT PT01910853T patent/PT1280540E/en unknown
- 2001-02-16 HU HU0300586A patent/HU227804B1/en active Protection Beyond IP Right Term
-
2002
- 2002-06-28 US US10/187,319 patent/US7012132B2/en not_active Expired - Fee Related
- 2002-08-21 IL IL151371A patent/IL151371A/en active IP Right Grant
- 2002-08-26 ZA ZA200206810A patent/ZA200206810B/en unknown
- 2002-09-09 NO NO20024296A patent/NO331935B1/en not_active IP Right Cessation
-
2003
- 2003-05-06 HK HK03103224A patent/HK1051004A1/en not_active IP Right Cessation
-
2004
- 2004-09-10 US US10/938,414 patent/US7122634B2/en not_active Expired - Fee Related
-
2008
- 2008-07-07 CY CY20081100709T patent/CY1108179T1/en unknown
-
2016
- 2016-04-27 LU LU93049C patent/LU93049I2/en unknown
- 2016-04-29 FR FR16C0016C patent/FR16C0016I2/en active Active
- 2016-05-02 BE BE2016C024C patent/BE2016C024I2/fr unknown
- 2016-05-06 LT LTPA2016014C patent/LTC1280540I2/en unknown
- 2016-05-09 HU HUS1600020C patent/HUS1600020I1/en unknown
- 2016-05-09 NL NL300808C patent/NL300808I2/en unknown
- 2016-05-10 NO NO2016007C patent/NO2016007I1/en unknown
- 2016-05-10 CY CY2016011C patent/CY2016011I2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300808I1 (en) | ||
| HK1043543A1 (en) | Modified factor VIII. | |
| EP1194164B8 (en) | Prion protein peptides and uses thereof | |
| GB0225474D0 (en) | Therapeutic agents | |
| DK1200418T3 (en) | Nematodicidal trifluorobutene | |
| DE60332137D1 (en) | Cyclohexyl-sulphone als gamma-sekretase-inhibitoren | |
| GB0108592D0 (en) | Therapeutic agents | |
| DE60126980D1 (en) | THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC ILLNESSES | |
| DK1244435T5 (en) | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases | |
| HK1069316A1 (en) | Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases | |
| MXPA04005079A (en) | Factor viii c2 domain variants. | |
| NO20025405D0 (en) | Modulators for TNF-alpha signaling | |
| DE60036122D1 (en) | USE OF EPLERENONE FOR THE TREATMENT OF RESTENOSIS | |
| CY1105317T1 (en) | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE | |
| CY1105142T1 (en) | USE OF 6-DIMETHYLAMINOMETHYL-1-PHENYL-CYCLOHEXANE SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF URINARY INCONTINENCE | |
| MXPA01009174A (en) | New pyridazine endothelin antagonists. |